Adam M. Brufsky, MD, PhD

Articles

Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC

July 3rd 2024

The panel examines how resistance mutations influence the effectiveness of subsequent treatment lines and delves into the process of selecting later-line therapies based on follow-up next-generation sequencing results.

Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway

July 2nd 2024

Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy.

Biomarker Testing Best Practices in HR+/HER2- mBC

June 26th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PI3 alterations, AKT alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

First-Line Treatment Options in HR+/HER2- and Challenges with Treatment Resistance

June 26th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PI3 alterations, AKT alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

Audience Q&A: Future Directions in Breast Cancer Care

August 31st 2022

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.

TROPiCS-02: Sacituzumab Govitecan in HR+/HER2- Breast Cancer

August 24th 2022

A brief review of data from the TROPiCS-02 clinical trial, which evaluated sacituzumab govitecan in HR+/HER2- metastatic or inoperable breast cancer.

DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast Cancer

August 24th 2022

Expert perspectives on the use of trastuzumab deruxtecan in HER2-low metastatic breast cancer in the context of the DESTINY-Breast04 trial.

HER2CLIMB: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

August 17th 2022

Focusing on the HER2CLIMB trial in HER2+ metastatic breast cancer, expert oncologists consider the value of a tucatinib-based regimen in this setting.

DESTINY-Breast03: T-DXd in Previously Treated HER2+ Breast Cancer

August 17th 2022

Comprehensive discussion on the DESTINY-Breast03 clinical trial evaluating trastuzumab deruxtecan in patients with previously treated HER2+ metastatic breast cancer.

Utilizing Brain MRI to Inform Treatment for HER2+ Metastatic Breast Cancer

August 10th 2022

A brief review of the value of using brain MRI to help determine treatment approaches for patients with HER2+ metastatic breast cancer.

KEYNOTE-522: Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in TNBC

August 10th 2022

Expert perspectives on the KEYNOTE-522 clinical trial, which utilized adjuvant pembrolizumab following neoadjuvant pembrolizumab plus chemotherapy in TNBC.

Adjuvant Abemaciclib in High-Risk HR+/HER2-, Node+ BC: The monarchE Trial

August 3rd 2022

Focusing on high-risk HR+/HER2- breast cancer, key opinion leaders review data with adjuvant abemaciclib from the monarchE clinical trial.

Adjuvant Olaparib in High-Risk gBRCA1/2 Mutated BC: The OlympiA Trial

August 3rd 2022

Comprehensive insight on trial data from OlympiA, which utilized adjuvant olaparib therapy in patients with gBRCA1/2 mutated breast cancer.

Next-Generation Sequencing Platforms for Late-Stage HR+ Breast Cancer

July 27th 2022

Shared insight on next-generation sequencing platforms, plasma- and tumor-based, for patients with late-stage HR+ breast cancer.

Optimizing Breast Cancer Management: Molecular Targets and Platforms for Testing

July 27th 2022

Expert oncologists identify molecular targets in breast cancer and review available testing platforms in the current treatment paradigm.

Dr. Brufsky on the Future Role of Chemotherapy in TNBC

September 17th 2020

Adam M. Brufsky, MD, PhD, discusses the future role of chemotherapy in triple-negative breast cancer.

Dr. Brufsky on the Risk COVID-19 Poses to Patients With Cancer

May 20th 2020

Adam M. Brufsky, MD, PhD, discusses the risk the coronavirus disease 2019 poses to patients with cancer.

Dr. Brufsky on Case Ascertainment Bias With COVID-19

March 20th 2020

Adam M. Brufsky, MD, PhD, discusses case ascertainment bias regarding the coronavirus 2019.

Dr. Brufsky on Trastuzumab Biosimilars in Breast Cancer

December 19th 2019

Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.

Dr. Brufsky on Challenges in Breast Cancer Treatment

November 8th 2019

Adam M. Brufsky, MD, PhD, discusses remaining challenges in breast cancer.

NEXT PAGE
PREVIOUS PAGE